Exscientia fires CEO—Chutes & Ladders fiercebiotech.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from fiercebiotech.com Daily Mail and Mail on Sunday newspapers.
Compugen Ltd. (NASDAQ: CGEN) (TASE: CGEN), a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, today announced the appointment of Michelle Mahler, M.D., as Chief Medical Officer, effective March 1, 2024. Michelle will succeed Henry Adewoye, M.D., who is leaving Compugen to pursue other opportunities effective February 29, 2024, after 6 years with Compugen.
Operator: Ladies and gentlemen, thank you for joining us today. Welcome to Compugen’s Third Quarter 2023 Results Conference Call. At this time, all participants are in a listen-only mode.
Operator
Ladies and gentlemen, thank you for joining us today. Welcome to Compugen Second Quarter 2021 Results Conference Call. [Operator Instructions] An audio webcast of this call is available in the Investors section of Compugen s website at www.cgen.com. As a reminder, today s call is being recorded.
I would now like to introduce Yvonne Naughton, Head of Investor Relations and Corporate Communications.
Yvonne Naughton
Head of Investor Relations and Corporate Communications
Thank you operator and thank you for joining us on the call today. Joining me to present prepared remarks are Anat Cohen-Dayag, President and CEO; and Ari Krashin, CFO and COO. For the Q&A session, we will also be joined by Henry Adewoye, CMO; and Eran Ophir, Vice President, Research and Drug Discovery. Before we begin, I would like to remind you, that during this call, the company may make projections or forward-looking statements regarding future events or business outlook; our development efforts and